KURA
Kura Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.36
+3.08%Oct 13, 2026, 11:30 UTC
Caspian Therapeutics and Kura Oncology, Inc. announced that IND-enabling development of KO-7246 is underway to support a planned Phase 1 proof-of-concept study assessing safety and endogenous insulin production.
Source:Oct 7, 2026, 11:15 UTC
Caspian Therapeutics and Kura Oncology, Inc. announced that they will host an investor webcast on October 13, 2026, at 4:30 p.m. ET to discuss Caspian's launch and preclinical data for KO-7246 in diabetes.
Source:Sep 9, 2026, 11:00 UTC
Kura Oncology launched Caspian Therapeutics, a separately financed company to advance menin inhibitors for diabetes, with $50 million financing led by BVF Partners.
Sep 8, 2026, 11:11 UTC
Kura Oncology, Inc. appointed Jennifer Fulk as Chief Financial Officer, effective September 8, 2026.
Aug 25, 2026, 12:29 UTC
Kura Oncology's CEO Wilson purchased shares of the company, disclosed after hours, causing the stock to rise 9.84% to $13.62.
Source:Aug 12, 2026, 20:02 UTC
Kura Oncology reported its second quarter 2026 financial results, including $9.1 million in net product revenue from KOMZIFTI (ziftomenib), up 57% over the first quarter, and approximately 115 new patient starts, up 35% over the first quarter.
Jun 4, 2026, 00:00 UTC
Kura Oncology, Inc. elected Diane Parks, Mary T. Szela, and Michael J. Vasconcelles as Class III Directors effective June 4, 2026.